Last updated: February 13, 2026
Overview of the Drug
NDC 49502-0501 corresponds to Verminac (generic: albendazole), an antiparasitic medication widely used to treat infections caused by helminths. Its primary indications include treatment of neurocysticercosis, echinococcosis, and other parasitic infestations. The drug is marketed mainly in the US, with variations in formulations and dosing depending on the specific condition.
Market Size and Growth Factors
The global antiparasitic drug market was valued at approximately $3.2 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of around 4.5% through 2027 [1]. US market share represents roughly 30% of global sales, driven by increasing parasitic infections, aging populations, and rising resistance issues.
In the US, prevalence rates for neurocysticercosis and echinococcosis are relatively stable, but awareness drives continued demand. The adoption of generic versions like albendazole further enhances accessibility and volume sales.
Regulatory Status and Market Penetration
Albendazole's patent expired in 2011, transitioning its market to generic status. Consequently, pricing is sensitive to generic competition. The drug is marketed as Verminac and other generics, with agency approval from the FDA for multiple indications.
Generics dominate sales volume, with branded versions accounting for less than 10% of revenue. The market shares are competitive owing to low manufacturing costs and high prescription volume.
Pricing Dynamics and Projection
Current US wholesale acquisition cost (WAC) for albendazole ranges from $0.15 to $0.30 per 200 mg tablet, depending on supplier and packaging. Retail prices are typically higher, influenced by insurance reimbursement, pharmacy markup, and dispensing fees.
Since the drug is off-patent, price projections show minimal fluctuation absent regulatory or market disruptions. Price stability is expected over the next five years with minor declines due to generic competition and procurement negotiations.
Future Price Trends and Market Drivers
- Generic Competition: Keeps prices low, with no major branded entries expected unless a novel formulation or delivery system is introduced.
- Manufacturing Costs: Remain low, pressuring retail prices downward.
- Regulatory Changes: Favorable regulatory pathways for biosimilar or new formulations could influence prices.
- Projected Wholesale Price Range (2023-2028): $0.14 - $0.25 per tablet.
- Market Impact of Supply Chain Dynamics: Potential for minor short-term price fluctuations because of manufacturing disruptions, but long-term prices remain stable.
Price Sensitivity and Cost-Effectiveness
Albendazole remains a cost-effective option for parasitic infections, especially in resource-limited settings. The low cost combined with broad FDA indications supports sustained demand.
Pricing Comparison with Similar Agents
| Drug |
Primary Indications |
Current US Wholesale Cost |
Market Share |
| Albendazole |
Neurocysticercosis, echinococcosis |
$0.15 - $0.30 per tablet |
>90% |
| Mebendazole |
Intestinal nematodes |
Slightly higher, ~$0.30-0.50 |
Smaller |
| Praziquantel |
Schistosomiasis, trematodiasis |
Higher, ~$1.00+ per tablet |
Niche |
Implications for Stakeholders
- Manufacturers: Little incentive to increase prices given the saturation from generics.
- Payers: Continued pressure for reimbursement rates aligned to low acquisition costs.
- Investors: Stability expected with moderate decline unless breakthroughs occur.
Key Takeaways
- NDC 49502-0501 (albendazole) is well-established, with low-cost generic options dominating the market.
- The US market is stable with a projected retail price of roughly $0.14 to $0.25 per tablet through 2028.
- Market growth depends on the prevalence of parasitic diseases, regulatory changes, and evolving resistance patterns.
- Price erosion due to competition limits upward movement; no significant branded or innovative premium segments exist.
FAQs
1. Will price increases occur for albendazole in the next five years?
Price increases are unlikely due to extensive generic competition and low manufacturing costs, with possible minor declines.
2. How does regulatory policy affect albendazole pricing?
Regulatory decisions favor generic approval pathways, reinforcing price stability and reducing potential for branded premium pricing.
3. Are there any upcoming formulations or alternatives that could shift market dynamics?
No major novel formulations or significant alternatives are expected in the near term, maintaining the status quo.
4. How does the drug's off-patent status impact profitability?
It limits profitability for manufacturers, keeping wholesale prices low and market share stable.
5. What are the key growth markets for albendazole outside the US?
Emerging markets in Africa, Asia, and Latin America see increased usage driven by infectious disease burden, but prices generally remain low.
Citations
[1] MarketWatch, "Global Antiparasitic Drugs Market Size," 2022.
